These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 15023878)

  • 1. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
    Mann DL; McMurray JJ; Packer M; Swedberg K; Borer JS; Colucci WS; Djian J; Drexler H; Feldman A; Kober L; Krum H; Liu P; Nieminen M; Tavazzi L; van Veldhuisen DJ; Waldenstrom A; Warren M; Westheim A; Zannad F; Fleming T
    Circulation; 2004 Apr; 109(13):1594-602. PubMed ID: 15023878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.
    Anker SD; Coats AJ
    Int J Cardiol; 2002 Dec; 86(2-3):123-30. PubMed ID: 12419548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.
    Deswal A; Bozkurt B; Seta Y; Parilti-Eiswirth S; Hayes FA; Blosch C; Mann DL
    Circulation; 1999 Jun; 99(25):3224-6. PubMed ID: 10385494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure.
    Bozkurt B; Torre-Amione G; Warren MS; Whitmore J; Soran OZ; Feldman AM; Mann DL
    Circulation; 2001 Feb; 103(8):1044-7. PubMed ID: 11222463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH.
    Coletta AP; Clark AL; Banarjee P; Cleland JG
    Eur J Heart Fail; 2002 Aug; 4(4):559-61. PubMed ID: 12167397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia and its relationship to clinical outcome in heart failure.
    Anand I; McMurray JJ; Whitmore J; Warren M; Pham A; McCamish MA; Burton PB
    Circulation; 2004 Jul; 110(2):149-54. PubMed ID: 15210591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Sandborn WJ; Hanauer SB; Katz S; Safdi M; Wolf DG; Baerg RD; Tremaine WJ; Johnson T; Diehl NN; Zinsmeister AR
    Gastroenterology; 2001 Nov; 121(5):1088-94. PubMed ID: 11677200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J; McHugh N; Singh A; Wajdula JS; Sato R
    Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-alpha inhibitors and congestive heart failure.
    Behnam SM; Behnam SE; Koo JY
    Skinmed; 2005; 4(6):363-8. PubMed ID: 16276152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of targeted anticytokine treatments in heart failure.
    Mohler KM; Murray KM; Mann DL; Francis G
    Circulation; 2000 Aug; 102(9):E65. PubMed ID: 10961980
    [No Abstract]   [Full Text] [Related]  

  • 13. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
    N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.
    Weisman MH; Paulus HE; Burch FX; Kivitz AJ; Fierer J; Dunn M; Kerr DR; Tsuji W; Baumgartner SW
    Rheumatology (Oxford); 2007 Jul; 46(7):1122-5. PubMed ID: 17470434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
    Sankar V; Brennan MT; Kok MR; Leakan RA; Smith JA; Manny J; Baum BJ; Pillemer SR
    Arthritis Rheum; 2004 Jul; 50(7):2240-5. PubMed ID: 15248223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial.
    Aaron SD; Vandemheen KL; Maltais F; Field SK; Sin DD; Bourbeau J; Marciniuk DD; FitzGerald JM; Nair P; Mallick R
    Thorax; 2013 Feb; 68(2):142-8. PubMed ID: 23161645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.